Form 4: Lyra Therapeutics Director James R. Tobin Acquires 32,000 Restricted Stock Units

Director James R. Tobin acquired 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Summary

• James R. Tobin, a director of Lyra Therapeutics, Inc., acquired 32,000 Restricted Stock Units (RSUs) on May 14, 2025.
• Each RSU represents a contingent right to receive one share of Lyra Therapeutics' common stock.
• The RSUs will vest 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026, or (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
• The transaction was reported in a Form 4 filing with the SEC on May 16, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction filing. The acquisition of RSUs by a director can be seen as a slightly positive sign, but it's not a strong indicator of future performance.

Positives

• The acquisition of RSUs by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon future events, including the company's annual meeting, a specific date in 2026, or a change in control.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

Lyra Therapeutics, James R. Tobin, Restricted Stock Units, RSU, Director, Form 4, Beneficial Ownership, Securities, Vesting